EUCTR2008-004856-57-IT进行中（未招募）不适用
A Phase II multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubiCin versus doxorubicin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO) - PICASSO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age ≥18 years 2. Histological or cytological documentation of sarcoma (excluding alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low grade liposarcoma) who have failed ≤2 prior regimens including adjuvant therapy, or ≤1 prior regimen for metastatic/unresectable disease, and for whom treatment with doxorubicin is considered medically acceptable. Prior treatment with IFOS is acceptable. 3. Have measurable disease as per RECIST criteria (Appendix 2) 4. ECOG Performance Status of 0 or 1 (Appendix 3) 5. Anthracyclin naïve 6. Life expectancy of ≥12 weeks 7. Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements conducted within 14 days prior to dosing: a. Hemoglobin ≥9.0 g/dL b. Absolute neutrophil count (ANC) ≥1,500/mm3 c. Platelet count ≥100,000/mm3 d. Total bilirubin ≤1.5×ULN (upper limit of normal) e. ALT and AST ≤2.5×ULN or 5×ULN with hepatic disease f. Partial thromboplastin [PT]-INR/activated partial thromboplastin time [PTT] <1.5×ULN (≤2.0×ULN for subjects on anticoagulation prophylactic regimen). Subjects who are being therapeutically anticoagulated with an agent such as Coumadin (warfarin sodium) or heparin are allowed provided there is no prior evidence of underlying abnormality in coagulation parameters. If an interaction between study drug and anticoagulant is suspected, anticoagulation monitoring should be increased as appropriate. g. Serum creatinine ≤ULN 8. Written informed consent must be obtained from a potential subject prior to the conduct of any study-specific procedures 9. Male and female subjects must agree to use adequate birth control measures/barrier control during the course of the trial 10. Women of childbearing potential must have a urine pregnancy test performed within 14 days of the start of treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has any one of the following sarcoma sub types: alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low grade liposarcoma. 2. Clinically evident congestive heart failure >Class II of the New York Heart Association (NYHA) guidelines (Appendix 4) 3. Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia, or ventricular arrhythmias classified as Lown III, IV, or V (Appendix 4) 4. History and/or signs of active coronary artery disease/ischemia with or without angina pectoris 5. Serious myocardial dysfunction defined as scintigraphically (MUGA [multiple gated acquisition scan], myocardial scintigram) or ultrasound-determined absolute left ventricular ejection fraction (LVEF) <45% 6. History of HIV infection 7. Prior nephrectomy or history of urinary tract obstruction 8. Active, clinically serious infection requiring systemic antibacterial, antifungal, or antiviral therapy 9. Any major surgery within 3 weeks prior to start of treatment 10. Metastatic brain or meningeal tumors, unless the subject is >6 months from definitive therapy and has a negative imaging study within 4 weeks of study entry. In addition, the subject must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable, provided the dose is stable for 1 month prior to study start, and following screening radiographic studies). 11. Previous malignancy (except cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis, & T1] or other malignancies curatively treated >5 years prior to entry) 12. Pregnancy or lactation 13. Substance abuse or medical, psychological, or social conditions that may interfere with the subject?s participation in the study or evaluation of the study results
研究者
相似试验
进行中（未招募）
不适用
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Effect of GSK2336805 With Pegylated Interferon and Ribavirin in Patients with Chronic Hepatitis C Infection.EUCTR2012-000523-40-BGGlaxoSmithKline Research and Devlopment Ltd115
进行中（未招募）
不适用
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Effect of GSK2336805 With Pegylated Interferon and Ribavirin in Patients with Chronic Hepatitis C Infection.Hepatitis C virusMedDRA version: 14.1Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 10022891 - InvestigationsEUCTR2012-000523-40-BEGlaxoSmithKline Research and Devlopment Ltd115
进行中（未招募）
不适用
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Effect of GSK2336805 With Pegylated Interferon and Ribavirin in Patients with Chronic Hepatitis C Infection.Hepatitis C virusMedDRA version: 16.0Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 100000004848EUCTR2012-000523-40-DEGlaxoSmithKline Research and Devlopment Ltd115
进行中（未招募）
1 期
/aeutropeniaMedDRA version: 20.0 Level: PT Classification code 10029354 Term: Neutropenia System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-002693-20-BGIlkogen Ilac San. ve Tic. A.S.60
进行中（未招募）
1 期
A Study of Aducanumab in Participants With MildCognitive Impairment due to Alzheimer’s Disease orWith Mild Alzheimer’s Disease Dementia to Evaluate theSafety of Continued Dosing in Participants WithAsymptomatic Amyloid-Related Imaging AbnormalitiesMild Cognitive Impairment due to Alzheimer's Disease and Mild Alzheimer's DementiaMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2018-002102-31-ITBIOGEN IDEC RESEARCH LIMITED500